Caribou Biosciences, Inc. (CRBU) saw its stock price decline by 4.65% on January 10, 2025, closing at $1.64, down from the previous day's close of $1.72. The stock opened at $1.72 and reached a low of $1.57 during the trading session, with a significant volume of 2,084,032 shares, which is 140.11% of its average daily volume. The downward pressure on the stock was primarily driven by the announcement of a class action securities lawsuit filed against the company by Levi & Korsinsky, LLP. The lawsuit alleges that Caribou Biosciences made false statements regarding the safety, efficacy, and commercial prospects of its CB-010 therapy and was at risk of insufficient capital to fund its operations. This legal development has raised concerns among investors, contributing to the stock's decline.